TY - JOUR
T1 - Potentiation of neurogenesis and angiogenesis by G-CSF after focal cerebral ischemia in rats
AU - Sehara, Yoshihide
AU - Hayashi, Takeshi
AU - Deguchi, Kentaro
AU - Zhang, Hanzhe
AU - Tsuchiya, Atsushi
AU - Yamashita, Toru
AU - Lukic, Violeta
AU - Nagai, Makiko
AU - Kamiya, Tatsushi
AU - Abe, Koji
N1 - Funding Information:
The authors thank Chugai Pharmaceutical Corporation Ltd. (Tokyo, Japan) for the generous gift of G-CSF. This work was partly supported by Grants-in-Aid for Scientific Research (B) 18390257, (C) 18590957 and (Hoga) 17659445 and the National Project on Protein Structural and Functional Analyses (Nakagawa A) from the Ministry of Education, Science, Culture and Sports of Japan, and by grants (Itoyama Y, Imai T and Kuzuhara S) from the Ministry of Health and Welfare of Japan.
PY - 2007/9/4
Y1 - 2007/9/4
N2 - Recently, granulocyte colony-stimulating factor (G-CSF) is expected to demonstrate beneficial effects on cerebral ischemia. Here, we showed the potential benefit of G-CSF administration after transient middle cerebral artery occlusion (tMCAO). Adult male Wistar rats received vehicle or G-CSF (50 μg/kg) subcutaneously after reperfusion, and were treated with 5-bromodeoxyuridine (BrdU, 50 mg/kg) once daily by the intraperitoneal route for 3 days after tMCAO. Nissl-stained sections at 7 days after tMCAO showed significant reduction of the infarction area (31%, P < 0.01). At 7 days after tMCAO, BrdU plus NeuN double-positive cells increased by 43.3% in the G-CSF-treated group (P < 0.05), and BrdU-positive endothelial cells were increased 2.29 times in the G-CSF-treated group, to a level as high as that in the vehicle-treated group (P < 0.01), in the periischemic area. Our results indicate that G-CSF caused potentiation of neuroprotection and neurogenesis and is expected to have practical therapeutic potential in treating individuals after ischemic brain injury.
AB - Recently, granulocyte colony-stimulating factor (G-CSF) is expected to demonstrate beneficial effects on cerebral ischemia. Here, we showed the potential benefit of G-CSF administration after transient middle cerebral artery occlusion (tMCAO). Adult male Wistar rats received vehicle or G-CSF (50 μg/kg) subcutaneously after reperfusion, and were treated with 5-bromodeoxyuridine (BrdU, 50 mg/kg) once daily by the intraperitoneal route for 3 days after tMCAO. Nissl-stained sections at 7 days after tMCAO showed significant reduction of the infarction area (31%, P < 0.01). At 7 days after tMCAO, BrdU plus NeuN double-positive cells increased by 43.3% in the G-CSF-treated group (P < 0.05), and BrdU-positive endothelial cells were increased 2.29 times in the G-CSF-treated group, to a level as high as that in the vehicle-treated group (P < 0.01), in the periischemic area. Our results indicate that G-CSF caused potentiation of neuroprotection and neurogenesis and is expected to have practical therapeutic potential in treating individuals after ischemic brain injury.
KW - Angiogenesis
KW - Colony-stimulating factor
KW - Granulocyte
KW - Neurogenesis
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=34248225837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248225837&partnerID=8YFLogxK
U2 - 10.1016/j.brainres.2007.01.149
DO - 10.1016/j.brainres.2007.01.149
M3 - Article
C2 - 17459352
AN - SCOPUS:34248225837
SN - 0006-8993
VL - 1151
SP - 142
EP - 149
JO - Brain Research
JF - Brain Research
IS - 1
ER -